Trial Profile

A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cedazuridine/decitabine (Primary) ; Decitabine
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Refractory anaemia; Refractory anaemia with excess of blasts; Sideroblastic anaemia
Focus Pharmacokinetics; Registrational
Acronyms ASCERTAIN
Sponsors Astex Pharmaceuticals

01 Nov 2024 Results evaluating Oral decitabine/cedazuridine versus intravenous decitabine, published in the British Journal of Haematology
23 Jan 2024 Results published in the Taiho Oncology Media Release
02 Jan 2024 According to a Taiho Oncology media release, data from this trial published in Lancet Haematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com